tuspetinib (HM43239)

News alerts, weekly reports and conference planners

Company:

Aptose Biosci, Hanmi

Drug class:

FLT3 inhibitor, SYK inhibitor, Myeloid kinome inhibitor

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B
FLT3 wild-type	Acute Myelogenous Leukemia	FLT3 wild-type	Acute Myelogenous Leukemia	HM43239 Sensitive: C3 – Early Trials HM43239 Sensitive : C3	HM43239 Sensitive: C3 – Early Trials HM43239 Sensitive : C3

Associations
(2)